You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKesson
Baxter
Dow
AstraZeneca

Last Updated: March 30, 2020

DrugPatentWatch Database Preview

JUXTAPID Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Juxtapid, and what generic alternatives are available?

Juxtapid is a drug marketed by Aegerion and is included in one NDA. There are nine patents protecting this drug.

This drug has ninety-two patent family members in thirty-seven countries.

The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lomitapide mesylate profile page.

US ANDA Litigation and Generic Entry Outlook for Juxtapid

Juxtapid was eligible for patent challenges on December 21, 2016.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for JUXTAPID
Drug Prices for JUXTAPID

See drug prices for JUXTAPID

Recent Clinical Trials for JUXTAPID

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Aegerion Pharmaceuticals, Inc.N/A
Aegerion Pharmaceuticals, Inc.Phase 1

See all JUXTAPID clinical trials

Recent Litigation for JUXTAPID

Identify potential future generic entrants

PTAB Litigation
PetitionerDate
Coalition for Affordable Drugs VIII2015-08-28
COALITION FOR AFFORDABLE DRUGS VIII, LLC2015-08-28

See all JUXTAPID litigation

Synonyms for JUXTAPID
1-(4-{9-[(2,2,2-trifluoroethyl)carbamoyl]-9H-fluoren-9-yl}butyl)-4-({[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}amino)piperidinium methanesulfonate
182431-12-5
202914-84-9
2522AH
431T125
82KUB0583F
9-(4-{4-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-piperidin-1-yl}-butyl)-9H-fluorene-9-carboxylic acid (2,2,2-trifluoro-ethyl)-amide
9-(4-{4-[(4''-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-piperidin-1-yl}-butyl)-9H-fluorene-9-carboxylic acid (2,2,2-trifluoro-ethyl)-amide
9-(4-{4-[(4''''-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-piperidin-1-yl}-butyl)-9H-fluorene-9-carboxylic acid (2,2,2-trifluoro-ethyl)-amide
9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-(4-(4-(((4'-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl)amino)-1-piperidinyl)butyl)-
9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-(4-(4-(((4'-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl)amino)-1-piperidinyl)butyl)-, methanesulfonate
9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-
AEGR 733
AEGR 773
AEGR-733
AEGR-733 mesylate
AEGR-733 mesylate;BMS-201038 mesylate;AEGR733 mesylate;BMS201038 mesylate;AEGR 733 mesylate;BMS 201038 mesylate
AEGR-733;BMS-201038
AEGR-733(Lomitapide)
AEGR-733Lomitapide
AEGR-773
AEGR733
AEGR773
AK547617
AKOS025149431
AKOS025149590
AOB2202
AS-56518
AS-75234
BCP06821
BCP10696
BDBM50098320
BMS 201038
BMS 201038-01
BMS 201038-04
BMS 201238
BMS-201038
BMS-201038 mesylate
BMS-201038-01
BMS-201038-04
BMS201038
C39H37F6N3O2
C39H37F6N3O2.CH4O3S
CHEBI:72297
CHEBI:72299
CHEMBL2105662
CHEMBL354541
CS-3423
CS-3424
D09637
D09638
DA-33433
DB-065402
DB08827
DTXSID50171294
DTXSID60174170
EX-A502
FT-0700260
FT-0750236
GTPL7439
HMS3653B17
HMS3743K11
HSDB 8218
HY-14667
HY-14668
J-690250
J-690260
Juxtapid (TN)
L0298
Lojuxta
Lojuxta (TN)
lomitapida
Lomitapide
Lomitapide (mesylate)
Lomitapide (USAN/INN)
Lomitapide [USAN:INN]
lomitapide mesilate
Lomitapide mesilate (JAN)
Lomitapide mesylate
Lomitapide mesylate (USAN)
Lomitapide mesylate [USAN]
lomitapide methanesulfonate
lomitapide monomesylate
lomitapide-mesylate
Lomitapide, >=98% (HPLC)
lomitapidum
MBBCVAKAJPKAKM-UHFFFAOYSA-N
methanesulfonic acid;N-(2,2,2-trifluoroethyl)-9-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]fluorene-9-carboxamide
N-(2,2,2-trifluoroethyl)-9-(4-(4-(4'-(trifluoroMet
N-(2,2,2-trifluoroethyl)-9-(4-(4-(4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamido)piperidin-1-yl)butyl)-9H-fluorene-9-carboxamide methanesulfonate
n-(2,2,2-trifluoroethyl)-9-(4-(4-(4'-(trifluoromethyl)biphenyl-2-ylcarboxamido)piperidin-1-yl)butyl)-9h-fluorene-9-carboxamide
N-(2,2,2-trifluoroethyl)-9-(4-(4-(4'-(trifluoromethyl)biphenyl-2-ylcarboxamido)piperidin-1-yl)butyl)-9H-fluorene-9-carboxamide methanesulfonate
N-(2,2,2-TRIFLUOROETHYL)-9-(4-{4-[4'-(TRIFLUOROMETHYL)-[1,1'-BIPHENYL]-2-AMIDO]PIPERIDIN-1-YL}BUTYL)-9H-FLUORENE-9-CARBOXAMIDE
N-(2,2,2-trifluoroethyl)-9-[4-(4-{2-[4-(trifluoromethyl)phenyl]benzamido}piperidin-1-yl)butyl]-9H-fluorene-9-carboxamide
N-(2,2,2-trifluoroethyl)-9-[4-(4-{2-[4-(trifluoromethyl)phenyl]benzamido}piperidin-1-yl)butyl]-9H-fluorene-9-carboxamide; methanesulfonic acid
N-(2,2,2-trifluoroethyl)-9-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]fluorene-9-carboxamide
N-(2,2,2-Trifluoroethyl)-9-[4-[4-[4'-(trifluoromethyl)-[1,1'-biphenyl]-2-ylcarboxamido]piperidin-1-yl]butyl]-9H-fluorene-9-carboxamide
N-(2,2,2-trifluoroethyl)-9-{4-(4-({(4'-(trifluoromethyl)biphenyl-2- yl)carbonyl}amino)piperidin-1-yl)butyl}-9H-fluorene-9-carboxamide
N-(2,2,2-trifluoroethyl)-9-{4-(4-({(4'-(trifluoromethyl)biphenyl-2-yl)carbonyl}amino)piperidin-1-yl)butyl}-9H-fluorene-9-carboxamide methanesulfonate
N-(2,2,2-trifluoroethyl)-9-{4-[4-({[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}amino)piperidin-1-yl]butyl}-9H-fluorene-9-carboxamide
N-(2,2,2-trifluoroethyl)-9-{4-[4-({[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}amino)piperidin-1-yl]butyl}-9H-fluorene-9-carboxamide methanesulfonate
NCGC00386364-05
Q1268941
Q27139887
QC-11679
QKVKOFVWUHNEBX-UHFFFAOYSA-N
s7633
s7635
SB16780
SC-14090
SCHEMBL2731380
SCHEMBL304604
SW220160-1
UNII-82KUB0583F
UNII-X4S83CP54E
X4S83CP54E
Z1876
ZINC27990463

US Patents and Regulatory Information for JUXTAPID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-005 Apr 23, 2015 RX Yes No   Start Trial   Start Trial   Start Trial
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-004 Apr 23, 2015 RX Yes No   Start Trial   Start Trial   Start Trial
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-005 Apr 23, 2015 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for JUXTAPID

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-006 Apr 23, 2015   Start Trial   Start Trial
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-001 Dec 21, 2012   Start Trial   Start Trial
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-002 Dec 21, 2012   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for JUXTAPID

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1725234 CR 2014 00002 Denmark   Start Trial PRODUCT NAME: LOMITAPID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF ELLER PIPERIDIN N-OXIDET DERAF, HERUNDER LOMITAPIDMESYLAT; REG. NO/DATE: EU/1/13/851/001-003 20130805
1725234 PA2014001,C1725234 Lithuania   Start Trial PRODUCT NAME: LOMITAPIDAS; REGISTRATION NO/DATE: EU/1/13/851/001, 2013-07-31 EU/1/13/851/002, 2013-07-31 EU/1/13/851/003 20130731
1725234 14C0003 France   Start Trial PRODUCT NAME: LOMITAPIDE , OU UN SEL PHARMACEUTIQUEMENT ACTIF DE CELUI-CI.; REGISTRATION NO/DATE: EU/1/13/851/001 20130805
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKesson
Baxter
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.